July 2025 in “Pakistan Journal of Intensive Care Medicine” In this randomized controlled trial, researchers observed that topical clobetasol propionate 0.05% was significantly more effective than topical tacrolimus 0.1% for treating alopecia areata, with a higher treatment success rate of 74.2% versus 45.2%, suggesting clobetasol as a preferred first-line topical therapy.
June 2022 in “Pakistan Journal of Medical and Health Sciences” This randomized controlled trial found that topical clobetasol propionate 0.05% ointment is significantly more effective than topical tacrolimus 0.1% ointment in promoting hair regrowth in patients with alopecia areata, with effective results observed in 79.31% of clobetasol users compared to 44.82% of tacrolimus users.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
28 citations
,
September 2021 in “JAAD Case Reports” This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.
22 citations
,
September 2008 in “International Journal of Dermatology” This case report describes a 41-year-old woman with segmental vitiligo and lichen sclerosus in the perineal region, where treatment with clobetasol ointment improved repigmentation and resolved many symptoms, although some scaling persisted.